Found: 20
Select item for more details and to access through your institution.
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 243, doi. 10.1002/hon.2961
- By:
- Publication type:
- Article
Differential transcriptomic profiling in ibrutinib‐naïve versus ibrutinib‐resistant Richter syndrome.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 302, doi. 10.1002/hon.2950
- By:
- Publication type:
- Article
Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T‐cell acute lymphoblastic leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 249, doi. 10.1002/hon.2948
- By:
- Publication type:
- Article
Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 280, doi. 10.1002/hon.2974
- By:
- Publication type:
- Article
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 160, doi. 10.1002/hon.2968
- By:
- Publication type:
- Article
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 191, doi. 10.1002/hon.2969
- By:
- Publication type:
- Article
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T‐cell lymphoma: A FIL phase 2 study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 307, doi. 10.1002/hon.2963
- By:
- Publication type:
- Article
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 269, doi. 10.1002/hon.2964
- By:
- Publication type:
- Article
Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 223, doi. 10.1002/hon.2958
- By:
- Publication type:
- Article
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 233, doi. 10.1002/hon.2959
- By:
- Publication type:
- Article
SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 287, doi. 10.1002/hon.2957
- By:
- Publication type:
- Article
Salvage therapy with "Dara‐KDT‐P(A)CE" in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 202, doi. 10.1002/hon.2949
- By:
- Publication type:
- Article
Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 172, doi. 10.1002/hon.2956
- By:
- Publication type:
- Article
Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 212, doi. 10.1002/hon.2955
- By:
- Publication type:
- Article
First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 297, doi. 10.1002/hon.2953
- By:
- Publication type:
- Article
Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre‐CAR T‐cell era.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 292, doi. 10.1002/hon.2952
- By:
- Publication type:
- Article
CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 258, doi. 10.1002/hon.2951
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 127, doi. 10.1002/hon.2890
- Publication type:
- Article
Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 181, doi. 10.1002/hon.2947
- By:
- Publication type:
- Article
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 129, doi. 10.1002/hon.2943
- By:
- Publication type:
- Article